Disclosed is a pharmaceutical formulation, in particular a pharmaceutical formulation in which the active ingredient comprises human antibodies to human interleukin I beta (IL- 1ß), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery. A histidine buffer system and a pH of 5.5-7 are present.